Study of Adalimumab in Subjects With Axial Spondyloarthritis
Summary
This study will study how well adalimumab works in the short and long term in people with axial spondyloarthritis who are not diagnosed as having either ankylosing spondylitis or psoriatic arthritis.
Study Design
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Conditions
Axial Spondyloarthritis
Intervention
Adalimumab, Placebo, Open-label Adalimumab
Location
Rheumatology Associates
Birmingham
Alabama
United States
35205
Status
Recruiting
Source
Abbott
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00939003
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Off-label Use
The practice of prescribing or using a drug outside the scope of the drug's official approved label as designated by a regulatory agency concerning the treatment of a particular disease or condition.
Axinella
A genus of SPONGES in the family Axinellidae, comprised of a choanosomal skeleton differentiated in the axial and extra-axial region. The type species is Axinella polypoides.
Therapeutic Misconception
Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.
Glaucoma, Open-angle
Glaucoma in which the angle of the anterior chamber is open and the trabecular meshwork does not encroach on the base of the iris.
Placebo Effect
An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.
Clinical Trials
Study of Adalimumab in Subjects With Peripheral Spondyloarthritis
This study will study how well adalimumab works in the short and long term in subjects with peripheral spondyloarthritis who are not diagnosed as having either ankylosing spondylitis or ps...
A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis
Based on published data and according to the approved product label for ankylosing spondylitis and psoriatic arthritis, it can be expected that adalimumab 40 mg every 14 days should be eff...
Reduction of signs and symptoms in patients with moderate to severely early axial spondyloarthritis (without radiological sacroiliitis) who have had an inadequate response to or do not tol...
ASIM - MRI and Biomarkers in Patients With Spondyloarthritis
Investigation of wholebody MRI and circulating biomarkers of inflammation, cartilage and bone metabolism in patients with spondyloarthritis treated with adalimumab. Furthermore to compare...
The objective of this study was to evaluate the safety and efficacy profile of Humira (adalimumab) in patients who had a sub-optimal response to prior systemic therapy. This open-label st...
PubMed Articles
Abstract Objective: A post hoc analysis of data from the adalimumab Crohn's disease (CD) maintenance trial (CHARM, NCT00077779), examining the relationship between adalimumab dosing and maintenance of...
We evaluated the efficacy, pharmacokinetics, and safety of adalimumab in Japanese patients with active ankylosing spondylitis (AS) who had an inadequate response to, or who were intolerant of, treatme...
To compare the efficacy and safety of adalimumab versus infliximab in an open-label prospective, comparative, multicenter cohort study of childhood noninfectious chronic uveitis.
This report describes the analytical validation and application of the homogeneous mobility shift assay (HMSA) method for the measurement of adalimumab and human antibodies-to-adalimumab (ATA) in seru...
Abstract Abstract To increase effectiveness of standard adalimumab treatment 40mg every other week (EOW) for patients with psoriasis, dose escalation to 40mg every week or addition of methotrexate (MT...
